R213
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 72
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ESTROGEN_RESPONSE_LATE+0.390
- ESTROGEN_RESPONSE_EARLY+0.330
- CHOLESTEROL_HOMEOSTASIS+0.310
- HYPOXIA+0.270
- PEROXISOME+0.270
- GLYCOLYSIS+0.260
- P53_PATHWAY+0.260
- FATTY_ACID_METABOLISM+0.250
- ANDROGEN_RESPONSE+0.210
- APICAL_SURFACE+0.210
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.410
- INTERFERON_GAMMA_RESPONSE-0.380
- INTERFERON_ALPHA_RESPONSE-0.360
- MYC_TARGETS_V2-0.260
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.210
- PI3K_AKT_MTOR_SIGNALING-0.210
- ANGIOGENESIS-0.200
- COMPLEMENT-0.160
- INFLAMMATORY_RESPONSE-0.160
- SPERMATOGENESIS-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1313112 | — | B | 0.718 |
| 2 | MNG384 | — | — | 0.711 |
| 3 | TCGA-A2-A0CU-01A-12R-A034-07 | — | B | 0.681 |
| 4 | SRR8613741 | — | F | 0.681 |
| 5 | TCGA-B6-A0RG-01A-11R-A056-07 | — | B | 0.643 |
| 6 | TCGA-A7-A13F-01A-11R-A12P-07 | — | B | 0.642 |
| 7 | MNG1099 | — | — | 0.641 |
| 8 | MNG772 | — | — | 0.633 |
| 9 | TCGA-BH-A0E1-01A-11R-A056-07 | — | B | 0.630 |
| 10 | MNG397 | — | — | 0.629 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ESTROGEN_RESPONSE_LATE | 0.390 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.330 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.310 | Remibrutinib | — uncovered |
| HYPOXIA | 0.270 | Idelalisib | — uncovered |
| PEROXISOME | 0.270 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.260 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.260 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.250 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.210 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.210 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.190 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.170 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.160 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.150 | Inavolisib | — uncovered |
| COAGULATION | 0.140 | Binimetinib | — uncovered |
| PROTEIN_SECRETION | 0.140 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.120 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| MYOGENESIS | 0.070 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.070 | Cobimetinib | — uncovered |